Page last updated: 2024-12-07

metadoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metadoxine, also known as meclofenoxate, is a synthetic compound with a complex structure that combines elements of an anti-inflammatory agent (meclofenamic acid) and a vitamin B6 analog. It is primarily studied for its potential neuroprotective effects, particularly in conditions like cognitive impairment, Alzheimer's disease, and stroke. Research suggests that metadoxine might enhance brain energy metabolism, protect against oxidative stress, and modulate neurotransmitter activity. While promising in preclinical studies, human trials have yielded mixed results. Its exact mechanism of action remains under investigation. Metadoxine is synthesized via a multi-step process that involves the coupling of meclofenamic acid with a pyridine derivative. Further research is needed to fully understand its therapeutic potential and safety profile.'

metadoxine: combination of above cpds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115198
MeSH IDM0114247

Synonyms (31)

Synonym
metadoxine
5-oxo-l-proline, compound with 5-hydroxy-6-methylpyridine-3,4-dimethanol (1:1)
einecs 277-913-8
D08186
metadoxil (tn)
74536-44-0
unii-ejq7m98h5j
metasin
ejq7m98h5j ,
alcoliv
metadoxil
AKOS015913487
S5060
5-oxo-l-proline compound with 5-hydroxy-6-methylpyridine-3,4-dimethanol (1:1)
metadoxine [mart.]
metadoxine [who-dd]
pyridoxine pyroglutamate
KS-5225
(5-hydroxy-6-methylpyridine-3,4-diyl)dimethanol (s)-5-oxopyrrolidine-2-carboxylate
pyridoxine-pyrrolidone carboxylat
(2s)-5-oxopyrrolidine-2-carboxylic acid; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
CS-0013958
HY-B1898
mfcd08704232
DTXSID80996053
metadoxin
CCG-267444
D70320
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid
metadoxil, metasin, pyridoxine-pyrrolidone carboxylat
EN300-7373245

Research Excerpts

Overview

Metadoxine is a pyridoxine-pyrrolidone carboxylate with significant scavenging property. It is an active drug for treatment of acute and chronic alcohol intoxication.

ExcerptReferenceRelevance
"Metadoxine is a pyridoxine-pyrrolidone carboxylate with significant scavenging property."( [The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis].
Blázovics, A; Fehér, J; Váli, L, 2005
)
1.35
"Metadoxine is an active drug for treatment of acute and chronic alcohol intoxication, affecting both liver and brain function. "( [Metadoxine in alcohol-related pathology].
Camarri, F; Corradini, P; Santoni, S; Zocchi, M, 1989
)
2.63

Treatment

Metadoxine treatment did not inhibit mitotic clonal expansion, but inhibited late-stage cell differentiation. Treatment with metad Oxine significantly decreased the half-life of ethanol in blood. Pretreatment with Metadoxin causes an inhibition in the formation of elevated quantities of saturated and mono-unsaturated fatty acids.

ExcerptReferenceRelevance
"Metadoxine treatment did not inhibit mitotic clonal expansion, but inhibited late-stage cell differentiation, suggesting that metadoxine may block the differentiation step of preadipocytes."( Metadoxine, an ion-pair of pyridoxine and L-2-pyrrolidone-5-carboxylate, blocks adipocyte differentiation in association with inhibition of the PKA-CREB pathway.
Ki, SH; Kim, HE; Kim, SG; Yang, YM, 2009
)
2.52
"Metadoxine-treated patients also exhibited a significantly greater decrease in blood alcohol concentration compared with those receiving standard treatment alone (-105.4 +/- 61.5 mg/dl versus -60.1 +/- 38.6 mg/dl, respectively)."( Efficacy of metadoxine in the management of acute alcohol intoxication.
Cruz Fuentes, C; Díaz Martínez, A; Díaz Martínez, MC; Villamil Salcedo, V,
)
1.23
"Pretreatment with Metadoxine causes an inhibition in the formation of elevated quantities of saturated and mono-unsaturated fatty acids."( Effects of metadoxine on cellular free fatty acid levels in ethanol treated rats.
Bombaci, G; Calabrese, V; Calderone, A; Rizza, V, 1993
)
1
"Treatment with metadoxine significantly decreased the half-life of ethanol in blood (from 6.70 +/- 1.84 to 5.41 +/- 1.99 hr; p < 0.013) and showed a faster rate of ethanol elimination. "( Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study.
Addolorato, G; Gasbarrini, G; Muzychenko, AP; Shpilenya, LS, 2002
)
2.11

Toxicity

ExcerptReferenceRelevance
"No significant toxic effect was observed in the 400 mg/kg group."( [Reproductive toxicity of metadoxine in rats].
Chen, JG; Lai, WQ; Mei, S; Wang, Y; Zhang, WY; Zhang, X; Zhu, HJ, 2003
)
0.62
" Metadoxine ER was generally well tolerated, with nausea (17% [10/58] vs 0% [0/59]), fatigue (31% [18/58] vs 27% [16/59]), and headaches (29% [17/58] vs 39% [23/59]) being the most frequently reported adverse effects for the metadoxine ER and placebo groups, respectively."( A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
Adler, LA; Aharon-Peretz, J; Ben-Hayun, R; Biederman, J; Daniely, Y; Manor, I; Megiddo, D; Newcorn, JH; Salomy, D; Weizman, A, 2012
)
1.49

Dosage Studied

ExcerptRelevanceReference
" The dosage of 1 600 mg/kg caused significant paralysis of hind legs, emaciation, and reduced weight gain."( [Reproductive toxicity of metadoxine in rats].
Chen, JG; Lai, WQ; Mei, S; Wang, Y; Zhang, WY; Zhang, X; Zhu, HJ, 2003
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (11.32)18.7374
1990's16 (30.19)18.2507
2000's18 (33.96)29.6817
2010's11 (20.75)24.3611
2020's2 (3.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.71 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index101.02 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (30.00%)5.53%
Reviews9 (15.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (55.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients [NCT02051842]Phase 4100 participants (Anticipated)Interventional2016-01-31Recruiting
Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention D [NCT02189772]Phase 283 participants (Actual)Interventional2014-08-31Completed
Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis [NCT02161653]Phase 4135 participants (Actual)Interventional2010-04-30Completed
A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome [NCT02126995]Phase 262 participants (Actual)Interventional2014-06-30Completed
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis [NCT02541045]Phase 3108 participants (Anticipated)Interventional2015-08-31Suspended(stopped due to lack of resources to finance the project)
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered as Repeated Doses to Healthy Volunteers [NCT01933997]Phase 116 participants (Actual)Interventional2013-08-31Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis [NCT02019056]Phase 290 participants (Actual)Interventional2010-11-30Completed
Efficacy Study of Metadoxine SR Formulation in ADHD Subjects [NCT00995085]Phase 143 participants (Actual)Interventional2009-10-31Completed
Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder [NCT01243242]Phase 2120 participants (Actual)Interventional2011-02-28Completed
Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder [NCT01685281]Phase 236 participants (Actual)Interventional2013-08-31Completed
A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease [NCT01504295]Phase 238 participants (Actual)Interventional2012-04-30Completed
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD) [NCT02059642]Phase 2/Phase 3300 participants (Actual)Interventional2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00995085 (1) [back to overview]Safety and Tolerability
NCT01243242 (3) [back to overview]Adult ADHD Quality of Life (AAQoL)- Measuring Change in Total Score of AAQoL From Visit 1 to Visit 6
NCT01243242 (3) [back to overview]Conners' Adult ADHD Rating Scales (CAARS™)
NCT01243242 (3) [back to overview]Test of Variables of Attention (TOVA) (Change in ADHD Score From Screening to Visit 6)
NCT02059642 (2) [back to overview]Change in Total ADHD Symptom Score With Adult Prompts of the Conners Adult ADHD Rating Scale:O-SV in ADHD Adults From Baseline to 6 Weeks
NCT02059642 (2) [back to overview]Safety Evaluation of Treatment on the Basis of Percentage of Participants With Treatment Emergent Adverse Events

Safety and Tolerability

Subjects were evaluated for general safety and tolerablity measures, including number of AEs and AEs related (possibly or likely) to study drug (NCT00995085)
Timeframe: 24 hours after drug adminstration

Interventionevents (Number)
Metadoxine SR2

[back to top]

Adult ADHD Quality of Life (AAQoL)- Measuring Change in Total Score of AAQoL From Visit 1 to Visit 6

The AAQoL scale provides a validated disease-specific measure of the impact of ADHD on quality of life.It is scored as an overall score (29 items) and four subscale scores: life productivity (11 items), psychological health (6 items), life outlook (7 items) and relationships (5 items). Individual items are scored on a five-point Likert-like scale from 'Not at all/Never' (1) to 'Extremely/Very Often' (5). (NCT01243242)
Timeframe: 6 weeks (from visit 1 baseline to visit 6)

Interventionunits on a scale (Mean)
METADOXINE(MG01CI)10.93
Placebo5.71

[back to top]

Conners' Adult ADHD Rating Scales (CAARS™)

The primary efficacy endpoint is the difference in change (decrease) in CAARS (Total ADHD Symptoms Score) between the study groups. The CAARS assess the presence and severity of ADHD symptoms and behaviors in adults. Respondents are asked to report their own experiences by rating items pertaining to their behavior/problems using a 4-point Likert-style format ranging from 0 ('Not at all', 'never') to 3 ('Very much', 'very frequently'). The scale measures ADHD symptoms using a 30-item questionnaire.Total score is the sum of all the items ,min=30 Max=90 (NCT01243242)
Timeframe: 6 weeks (from visit 1 baseline to visit 6)

Interventionunits on a scale (Mean)
METADOXINE(MG01CI)-12
Placebo-8.93

[back to top]

Test of Variables of Attention (TOVA) (Change in ADHD Score From Screening to Visit 6)

The TOVA is a computerized test that provides information about an individual's sustained attention, speed and consistency of responding, and behavioral self-regulation and executive functioning. ADHD score is a comparison of the subject's response to the CPT test to those of an ADHD group, and is reported as a Z-score. An ADHD score of -1.80 and less fits the profile of the ADHD sample. A score of more than -1.80 (more positive) does not fit the ADHD profile. When comparing ADHD scores the higher the ADHD score the better the performance. (NCT01243242)
Timeframe: 6 weeks( visit 1 baseline to visit 6)

InterventionZ score (Mean)
METADOXINE(MG01CI)4.96
Placebo3.01

[back to top]

Change in Total ADHD Symptom Score With Adult Prompts of the Conners Adult ADHD Rating Scale:O-SV in ADHD Adults From Baseline to 6 Weeks

Primary efficacy endpoint: change from Baseline in the total ADHD symptom score with adult prompts of the CAARS-Inv. The CAARS is a scale to assess the presence and severity of ADHD symptoms and behaviors in adults. During an interview with the investigator, subject rates items pertaining to their behavior using a 4-point Likert-style format ranging from 0 ('Not at all') to 3 ('Very much). The scale measures ADHD symptoms across clinically significant domains using a 30 item questionnaire, while examining the manifestations of those symptoms. The scale includes an assessment of 9 inattentive symptoms (Subset A) and 9 hyperactive & impulsive symptoms (Subset B). The total ADHD symptom score, Subset C (the sum of the inattentive symptom scores from Subset A and the hyperactive & impulsive symptoms from Subset B) is the primary outcome measure. Scores of the scale for Subset C, comprised of scores from 18 questions,range from 0 (no ADHD symptoms) to 54, highest rating of ADHD symptoms. (NCT02059642)
Timeframe: baseline, 6 weeks

InterventionChange in Score from Baseline (Least Squares Mean)
Placebo-9.9
MG01CI (1400 mg)-12.0

[back to top]

Safety Evaluation of Treatment on the Basis of Percentage of Participants With Treatment Emergent Adverse Events

Safety assessments will be based on changes from Baseline of clinical AEs reported by the subject or observed by the Investigator and concomitant medication use, treatment adherence (eg, dropouts due to AEs) (NCT02059642)
Timeframe: 6 weeks

InterventionPercentage of participants with TEAEs (Number)
Placebo66.4
MG01CI (1400 mg)56.8

[back to top]